San Francisco, June 17 : Tesla and SpaceX CEO Elon Musk has said that his brain-computer interface company Neuralink is likely to begin the first human trial this year.
Addressing the VivaTech trade fair in Paris late on Friday, Musk said that "its looking like the first case will be later this year".
Last month, Neuralink received US Food and Drug Administration (FDA) approval to begin its first-in-human clinical study, which means that actual humans could have a Neuralink device implanted in their heads."We are excited to share that we have received the FDAs approval to launch our first-in-human clinical study," Neuralink said.
"This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," it added.On receiving the FDA approval, Musk also tweeted congratulating the Neuralink team.
In March, the FDA had rejected Neuralinks bid to implant a chip in a human brain over safety risks.In December last year, Musk had claimed Neuralinks device is ready for human trials and he was expecting to do so in about six months after experimenting it on pigs and monkeys.
However, Musks Neuralink would not be the first to implant a brain-computer interface into humans.Neuralink rival Synchron launched human trials on six severely paralysed patients in the US to enable them to control digital devices hands-free, using just thoughts last year in May.na/shb/ #trial #Elon #Musk #Bid #San Francisco #Paris #Tesla #Cisco #Elon Musk #SpaceX.
Latest News
Download App
Channels
HomeEnglish NewsTeluguStop Exclusive StoriesFlash/Breaking NewsTrending NewsPoliticalMovieHealth TipsCrime NewsMovie ReviewsNRI NewsViral VideosBhakthi/DevotionalPress ReleasesViral StoriesQuotesPhoto TalksBaby Boy NamesBaby Girl NamesCelebrity ProfilesFollow Us!
Contact Us!
TeluguStop.com Media, Siya Residency, Sri Sri Circle, Khammam, Telangana- 507002info@telugustop.comPh No : 999-279-9973
About Us!
About UsJobsAdvertisingDMCA / RemovalTerms of UsePrivacy Policy